4Chan PK,Chang AR,Cheung JL,et al.Determinants of cervical human papillomavirus infection:differences between highand low-oncogenic risk types[J].J Infect Dis,2002,185 (1):28-35.
5Beby DA,Bourgoin A,Ragot S,et al.Human papillomavirus infection of the cervix uteri in women attending a health examination center of the French Social Security[J].J Med Virol,2004,73 (2):262-268.
6Munoz N,Bosch FX,Sanjose S,et al.Epidemiologic classification of human papillomavirus types associated with cervical cancer.[J].N Engl J Med,2003,348(6):518-527.
7zur Hausen H.Papillomaviruses and cancer:from basic studies to clinical application[J].Nat Rev Cancer,2002,2 (5):342 -350.
8WHO.Progress in reproductive health research[J/OL].http://www.who.int/ reproductive-health/hrp/progress/60/news60.html,2005-11-02.
9Hapangama DK,Critchley HO,Henderson TA,et al.Mifepristone-induced vaginal bleeding is associated with increased immunostaining for cyclooxygenase-2 and decrease in prostaglandin dehydrogenase in luteal phase endometrium[J].Clin Endocrinol Metab,2002,87(11):5229-5234.
10Repine T,Osswald M.Menorrhagia due to a qualitative deficiency of plasminogen activator inhibitor-1:case report and literature review[J].Clin Appl Thromb Hemost,2004,10(3):293 -296.
